Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Gains from Investment Securities (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Gains from Investment Securities for 5 consecutive years, with -$74000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Investment Securities fell 107.52% year-over-year to -$74000.0, compared with a TTM value of $748000.0 through Sep 2025, down 83.43%, and an annual FY2024 reading of $2.4 million, up 355.18% over the prior year.
  • Gains from Investment Securities was -$74000.0 for Q2 2025 at Autolus Therapeutics, down from $71000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.8 million in Q4 2022 and bottomed at -$3.8 million in Q3 2023.
  • Average Gains from Investment Securities over 4 years is $1.2 million, with a median of $656000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities surged 117.44% in 2024, then crashed 107.52% in 2025.
  • Year by year, Gains from Investment Securities stood at $9.8 million in 2022, then crashed by 70.6% to $2.9 million in 2023, then crashed by 73.88% to $751000.0 in 2024, then tumbled by 109.85% to -$74000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for AUTL at -$74000.0 in Q2 2025, $71000.0 in Q1 2025, and $751000.0 in Q4 2024.